Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Quest Diagnostics (DGX)

Quest Diagnostics Q1 revenue rises 12.1% to $2.65 billion; reported EPS up 12.8%

Positive Impact 4 of 5 earnings Written later

Quest Diagnostics reported first quarter 2025 revenue of $2.65 billion, up 12.1% from a year earlier, and reported diluted EPS of $1.94, up 12.8%. The company raised its full-year 2025 reported diluted EPS outlook to $8.62 to $8.87 from $8.34 to $8.59 and reaffirmed its revenue and adjusted EPS guidance, which matters to shareholders because the earnings outlook moved up while the top-line outlook held.

Key points

  • Q1 2025 net revenues $2.65 billion, up 12.1%; organic requisition volume fell 0.9%
  • Reported diluted EPS $1.94, up 12.8%; adjusted diluted EPS $2.21, up 8.3%
  • Full-year 2025 reported diluted EPS now expected at $8.62 to $8.87, up from $8.34 to $8.59
  • Full-year 2025 revenue guidance of $10.70 billion to $10.85 billion and adjusted diluted EPS of $9.55 to $9.80 unchanged

The filing

CompanyQuest Diagnostics (DGX)
Form8-K, current report
Filed with the SECApr 22, 2025, 6:44 AM ET
Accession number0001022079-25-000116

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 22, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.